Your AI-Trained Oncology Knowledge Connection!

Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 6

Recent findings from BESPOKE

July 11, 2024

By Scott Kopetz, MD, PhD, FACP
Arvind Dasari, MD, MS

Opinion

Video

Key opinion leaders analyze recent findings from the BESPOKE study.

EP: 1.Overview of colorectal cancer and its management

EP: 2.Background on Colorectal Cancer Screening and its Role in Patient Care

EP: 3.Circulating Tumor DNA Detection Techniques

EP: 4.Describing the Value of ctDNA in Clinical Practice

EP: 5.Clinical study of ctDNA-based MRD detection and INTERCEPT program update

EP: 6.Recent findings from BESPOKE

EP: 7.Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice

EP: 8.Key Considerations for Selection of ctDNA Detection Methods

EP: 9.Clinical Utility of ctDNA Testing

EP: 10.Barriers to Implementing ctDNA Testing

EP: 11.ctDNA Testing in a CRC Clinical Scenario

EP: 12.ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial

EP: 13.Interpreting and Communicating ctDNA Results

EP: 14.Addressing Gaps in ctDNA Testing

EP: 15.Exploring the Future of ctDNA and Novel Treatment Strategies

BESPOKE Interim analysis: ctDNA for informing ACT in stage II/III CRC (Kasi, et al. ASCO GI 2024. Abstract 9.)

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

2 experts are featured in this series.

1 expert is featured in this series.

2 experts are featured in this series.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.